Faiez Zannad is Professor of Therapeutics at the University of Lorraine in Nancy, France. He earned his MD degree and cardiology specialty at the University of Lorraine in 1979 and PhD degree in clinical pharmacology at the University of Lyon in Lyon, France, in 1984. During his PhD study, he also completed a fellowship at the MRC Clinical Pharmacology unit, Oxford, UK. Pr Zannad is currently Head of the Division of Heart Failure and Hypertension and Director of the Inserm Clinical Investigation Center at “Institut Lorrain du Coeur et des Vaisseaux” in the Centre Hospitalier et Universitaire of Nancy.
Pr Zannad coordinates two EU FP7 grants in heart failure: HOMAGE (omics biomarkers for mechanistic phenotyping and prediction of drug response [www.homage-hf.eu]) and FIBROTARGETS (fibrosis as a biotargets [www.fibrotargets.eu]). As the primary investigator or member of the oversight committees in major clinical trials, Pr Zannad has made significant contributions to evidence-based heart failure life-saving therapy, mainly with beta-blockers (CIBIS) and mineralocorticoid receptor antagonists (RALES, EPHESUS, EMPHASIS-HF). He pioneered cardiovascular outcome trials in chronic kidney disease (FOSIDIAL, AURORA, ALCHEMIST) and the one of the first cardiovascular safety trials on glucose-lowering drugs in diabetes (EXAMINE). Pr Zannad has served as Chairman of the French Society of Hypertension, Chairman of the ESC Working Group on pharmacology and drug therapy, and board member of the ESC Heart Failure Association.
He was Founder and is currently Chairman of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international meeting dedicated to the science of clinical trials, and of the International Workshop on Biomarkers in heart failure. He has authored more than 550 scientific publications.
Dr. Milton Packer is the Distinguished Scholar in Cardiovascular Science at the Baylor University Medical Center in Dallas. He has been the principal investigator of 20 multicenter trials that have evaluated novel interventions for the treatment of acute and chronic heart failure. He has served frequently as a member of government advisory committees, study sections, task forces or Data and Safety Monitoring Boards for the NIH. He served as a member of the Cardiac and Renal Drugs Advisory Committee to the US Food and Drug Administration from 1986-1992 and then as its Chair from 1997-2001, and he continues to serve on various FDA advisory committees. Dr. Packer was President of the Heart Failure Society of America from 2000-2002 and has served on numerous guidelines and standards committees for the American Heart Association and American College of Cardiology. He has received many teaching awards and has mentored dozens of young clinical investigators, many of whom have become leaders in basic and clinical research.
Bertram Pitt is a professor of medicine emeritus at the University of Michigan, School of Medicine. Dr Pitt obtained his MD degree from the University of Basel in Switzerland. He completed a fellowship in cardiology at the Johns Hopkins University School of Medicine and remained on the faculty until he left to direct the division of cardiology at the University of Michigan. He is currently chairman of the steering committee of the NHLBI TOPCAT trial; co-chairman of the Emphasis-HF trial, chairman of Break- DHF, co-chairman of STOP-CKD, co-chairman of Exceed, co-chairman of Escape-SHF and Escape-DH F, chairman of a study evaluating the role of an aldostereone synthase inhibitor in patients with HF and is a member of the executive committee of the Accomplish trial. He has been awarded the James B. Herrick Award by the Council of Clinical Cardiology of the American Heart Association and has been elected to the Society of Scholars of the Johns Hopkins University.
Alex Nowbar is a researcher at the National Heart and Lung Institute, Imperial College London, and is an investigator for the ORBITA-2 trial. She completed her medical degree at Imperial College London in 2015 and has continued her medical training in North West London. She was winner of BMJ Award for UK Research Paper of the Year 2015 for the DAMASCENE study. She has been writing the BMJ weekly journal review column since 2018.
I'm Larry Husten and I write CardioBrief, which is intended to be a useful and reliable source for new and important information about cardiovascular medicine and, occasionally, more general health, medicine, and science topics.
Prior to starting CardioBrief early in 2009 I was the editor of TheHeart.Org, from its inception in 1999 until December 2008. Following the purchase of TheHeart.Org by WebMD in 2005 I also served as the editorial director of WebMD professional news, encompassing TheHeart.Org and Medscape Medical News. (Click here if you'd like to read more about what happened to TheHeart.Org after I left.)
From January 2010 until June 2015 I was a consulting editor and news director at CardioExchange, an online cardiology community published by the New England Journal of Medicine.
Before helping to start TheHeart.Org I was a freelance medical journalist who wrote for the Lancet, the New York Times, Discover, and many other medical and computer publications. In 1994-1995 I was a Knight Science Journalism Fellow at MIT. I have a PhD in English from the State University of New York at Buffalo and I drove a taxicab in New York City before falling into a career in medical journalism.